Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

An ENCORE for emricasan
February 2016
EDIT CONNECT

SHARING OPTIONS:

SAN DIEGO—Conatus Pharmaceuticals Inc. has begun active patient recruitment for ENCORE-NF, a Phase 2b clinical trial of emricasan, Conatus’ first-in-class, orally active pan-caspase inhibitor, in patients with nonalcoholic steatohepatitis (NASH). The trial will evaluate differentiated dosing and efficiency of emricasan in NASH fibrosis and collect long-term safety data to support Conatus' initial registration focus in liver cirrhosis. The primary endpoint is a biopsy-based improvement in fibrosis by at least one stage versus placebo using NASH CRN without worsening of steatohepatitis, and top-line results from the study are expected in 2018.
Dr. Steven J. Mento, Conatus co-founder, president and CEO, said that “Emricasan’s mechanism of action targets both apoptosis and inflammation, both of which are key drivers of liver fibrosis in NASH. In preclinical models of NASH and [nonalcoholic fatty liver disease], emricasan treatment improved liver histology, including reductions in both liver fibrosis and liver inflammation.”
 
Code:

Back



PAGE UTILITIES


CONTACT US
DDNEWS
Published by Old River Publications LLC
19035 Old Detroit Road
Rocky River, OH USA 44116
Ph: 440-331-6600  |  Fax: 440-331-7563
 
© Copyright 2017 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.